Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabidiolic acid (CBDA) is a naturally occurring cannabinoid found in the Cannabis plant, primarily in fiber and seed-oil hemp varieties. It is the acidic precursor to cannabidiol (CBD), formed through the biosynthetic pathway involving cannabidiolic acid synthase, which converts cannabigerolic acid into CBDA. Upon exposure to heat or light, CBDA undergoes decarboxylation to form CBD[1][4]. As a small molecule phytocannabinoid, CBDA has been investigated for potential therapeutic effects and is currently under clinical investigation for topical use in degenerative hallux disorders[8]. Its mechanism of action remains under study; while it shares some properties with CBD, including possible anti-inflammatory and neuroprotective effects, its precise pharmacological targets are not fully established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiolic acid.